October 12, 2005 -- The National Institute of Allergy and Infectious Diseases (NIAID) has issued more than $47 million for grants, contracts and interagency agreements as part of a new National Institutes of Health (NIH) research program on Medical Countermeasures Against Radiological and Nuclear Threats. This program emphasizes product development and seeks to develop preventions and treatments for radiation sickness following a terrorist attack.

"Radiological dirty bombs or nuclear explosive devices are among the potential terrorist threats Americans face. Our new medical countermeasures program will help protect the public from radiation should such an attack ever occur," says NIAID Director Anthony S. Fauci, M.D.

NIAID is the lead institute at NIH for the development of biodefense countermeasures. Its research portfolio includes many in-depth studies of the immune system, which is especially vulnerable to radiation. For these reasons, the Department of Health and Human Services asked NIAID to coordinate and lead the development of a robust NIH research program on medical countermeasures to radiation.

Funding for this program is from the Department of Health and Human Services Office of Public Health Emergency Preparedness. Twelve grants, four contracts and two interagency agreements have recently been formalized through this new NIH research program. While each award has a specific focus connected to product development or basic research, the sum of the efforts covers the necessary components to develop medical countermeasures from concept through licensure.

Eight universities or research institutes have received grants to establish Centers for Medical Countermeasures Against Radiation. These centers will focus on basic and applied research to develop new products for measuring radiation exposure, to protect against exposure and to minimize and treat the effects of exposure to a wide range of radioactive compounds.

Funding for the centers totals about $28.7 million for fiscal year 2005. NIAID plans to fund the centers for five years. The principal investigators and approximate funding for fiscal year 2005 for each center are as follows:

* Paul Okunieff, M.D., University of Rochester Medical Center, Rochester, NY, $4.3 million

* David J. Brenner, Ph.D., D.Sc., Columbia University Medical Center, New York, NY, $5.0 million

* Nelson J. Chao, M.D., Duke University, Durham, NC, $4.4 million

* George Georges, M.D., Fred Hutchinson Cancer Research Center, Seattle, WA, $4.5 million

* John Moulder, Ph.D., Medical College of Wisconsin, Milwaukee, WI, $3.7 million

* William H. McBride, Ph.D., D. Sc., University of California, Los Angeles, CA, $2.8 million

* Alan D. D'Andrea, M.D., Dana-Farber Cancer Institute, Boston, MA, $2.0 million

* Joel S. Greenberger, M.D., University of Pittsburgh, $2.0 million

NIAID awarded a smaller set of grants to four other research organizations to support projects focused on protecting the immune system from radiation or restoring the immune system following radiation exposure. These 18-month accelerated product development awards total $4.0 million:

* Andrei Gudkov, Ph.D., D.Sc., Cleveland BioLabs, Inc., Cleveland, OH, $1.5 million

* George Georges, M.D., Fred Hutchinson Cancer Research Center, Seattle, WA, $1.5 million

* Amelia Bartholomew, M.D., University of Illinois at Chicago, Chicago, IL, $500,000

* Thomas MacVittie, Ph.D., University of Maryland School of Medicine, Baltimore, MD, $500,000

Two universities and two companies are receiving contracts for developing medical countermeasures products. The largest of these contracts, Medical Countermeasures Against Radiological Threats: Product Development Support Services, was awarded to the University of Maryland School of Medicine. The university will receive about $9.3 million in fiscal year 2005.

The University of Kentucky, Lexington, Nanotherapeutics of Alachua, FL, and SRI International of Menlo Park, CA, also are receiving contracts for Development of Improved DTPA for Radionuclide Chelation. DTPA (short for the chemical diethylenetriaminepentaacetate) can be used to remove certain radioactive compounds from the body. If a person is exposed to one of these compounds, DTPA can be given intravenously to help eliminate the contamination. For use following a terrorist attack, however, DTPA would be practical only in an easier-to-administer form. The contractors will seek to develop alternate ways to effectively administer DTPA, either by inhalation, oral liquid or pill.

NIAID has awarded 14-month contracts with renewal options to

* University of Kentucky, $816,115

* Nanotherapeutics, Inc., $776,314

* SRI International, $931,123


NCI, also part of the National Institutes of Health, received $1 million through a 2005 interagency agreement to develop compounds to protect against radiation exposure; conduct epidemiological studies on the medical consequences of radiation exposure; and identify compounds the body produces when exposed to radiation.

To learn more about the NIAID research program on medical countermeasures against radiological and nuclear threats, visit the program's Web site, http://www3.niaid.nih.gov/research/topics/radnuc/.

NIAID is part of the National Institutes of Health, the nation's medical research agency. For more information about NIH and its programs, visit http://www.nih.gov.